HCV Genotype Testing Prior to Treatment
Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom HCV genotype testing was performed prior to initiation of antiviral treatment (paired with NQF 0395)
-
Group/Practice
Individual Clinician
Measure Info
ACP does not support NQF 0396: “HCV Genotype Testing Prior to Treatment.” Although this practice represents the standard of care, the evidence presented in support of the measure shows a very small gap in care (about 10%), which could be explained by error in data collection. The small potential benefit is outweighed by the burden of measurement.